NEOS Investment Management LLC Invests $380,000 in Genmab A/S (NASDAQ:GMAB)

NEOS Investment Management LLC purchased a new position in shares of Genmab A/S (NASDAQ:GMABFree Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 11,946 shares of the company’s stock, valued at approximately $380,000.

Other institutional investors have also modified their holdings of the company. Headlands Technologies LLC purchased a new stake in shares of Genmab A/S during the 3rd quarter worth approximately $27,000. Pinnacle Bancorp Inc. boosted its stake in shares of Genmab A/S by 315.8% during the 4th quarter. Pinnacle Bancorp Inc. now owns 840 shares of the company’s stock worth $27,000 after acquiring an additional 638 shares in the last quarter. NBC Securities Inc. purchased a new stake in shares of Genmab A/S during the 3rd quarter worth approximately $37,000. Principal Securities Inc. purchased a new stake in shares of Genmab A/S during the 4th quarter worth approximately $77,000. Finally, Advisors Preferred LLC purchased a new stake in shares of Genmab A/S during the 4th quarter worth approximately $82,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GMAB shares. Truist Financial boosted their price target on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Monday. BMO Capital Markets upgraded Genmab A/S from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Finally, Morgan Stanley restated an “underweight” rating on shares of Genmab A/S in a research report on Tuesday, March 26th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, Genmab A/S has a consensus rating of “Hold” and a consensus price target of $49.25.

Get Our Latest Stock Report on Genmab A/S

Genmab A/S Stock Performance

Shares of GMAB opened at $28.74 on Thursday. The stock has a fifty day moving average of $29.03 and a two-hundred day moving average of $29.72. The company has a market capitalization of $19.00 billion, a PE ratio of 23.95, a price-to-earnings-growth ratio of 1.04 and a beta of 0.99. Genmab A/S has a fifty-two week low of $26.32 and a fifty-two week high of $42.72.

Genmab A/S (NASDAQ:GMABGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.16 earnings per share for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $603.30 million during the quarter, compared to the consensus estimate of $594.23 million. Genmab A/S had a return on equity of 18.90% and a net margin of 30.74%. As a group, equities research analysts forecast that Genmab A/S will post 1.11 earnings per share for the current fiscal year.

Genmab A/S Company Profile

(Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMABFree Report).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.